ADMA BIOLOGICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $8.21M, a 22.80% decline year-over-year.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $17.19M.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $41.91M, a 52.75% decline year-over-year.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $10.64M.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for fiscal 2022 was $64.64M, a 46.64% decline from fiscal 2021.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for fiscal 2021 was $121.14M, a 7.66% decline from fiscal 2020.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for fiscal 2020 was $131.20M, a 171.08% increase from fiscal 2019.
- ADMA BIOLOGICS, INC. stock issued during period, value, new issues for fiscal 2019 was $48.40M, a 12.70% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $64.64M 10-K · filed 2025-03-18 | |
| 2021-12-31 | $121.14M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $8.21M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $17.19M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $41.91M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $131.20M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $10.64M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $88.70M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $48.40M 10-K · filed 2020-03-13 | |
| 2018-12-31 | $42.94M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $39.20M 10-K · filed 2019-03-13 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $12.90M 10-K · filed 2018-03-29 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $10.25M 10-K · filed 2017-02-24 |
| 2015-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | |
| 2015-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | |
| 2015-03-31 | $10.23M 10-Q · filed 2015-05-12 | |
| 2013-12-31 | $26.60M 10-K · filed 2015-03-09 | |
| 2012-06-30 | -$42.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | |
| 2012-03-31 | $15.65M 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |